Ignite Creation Date:
2024-05-05 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00043407
Status:
COMPLETED
Last Update Posted:
2009-02-12
First Post:
2002-08-08
Brief Title:
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase III Open Label Multi-Center Study For The Evaluation Of CPG 7909 In Patients With Stage Iv Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CPG 7909 given alone to patients with renal cell cancer after their nephrectomy CPG 7909 is as a subcutaneous injection once per week for up to 24 weeks Up to 40 patients will be included in the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CO10 A8501022 | None | None | None |